Abstract:Xeroderma pigmentosum (XP) is a rare autosomal recessive disease caused by pathogenic variants in seven nucleotide excision repair genes (XPA to XPG) and POLH involved in translesion synthesis. XP patients have a >1000-fold increased risk for sunlight-induced skin cancers. Many Japanese XP-A patients have severe neurological symptoms due to a founder variant in intron 3 of the XPA gene. However, in the United States we found XP-A patients with milder clinical features. We developed a simple scoring scale to assess XP-A patients of varying neurological disease severity. We report 18 XP-A patients examined between 1973 and 2023 under an IRB approved natural history study. Using our scale, we classified our XP-A cohort into severe (n = 8), intermediate (n = 5), and mild (n = 5) disease groups at age 10 years. DNA repair tests demonstrated greatest reduction of DNA repair in cells from severe patients as compared to cells from mild patients. Nucleotide sequencing identified 18 germline pathogenic variants in the 273 amino acid, 6 exon-containing XPA gene. Based on patient clinical features, we associated these XPA variants to severe (n = 8), intermediate (n = 6), and mild (n = 4) clinical phenotypes in the patients. Protein structural analysis showed that nonsense and frameshift premature stop codon pathogenic variants located in exons 3 and 5 correlated with severe disease. Intermediate disease correlated with a splice variant at the last base in exon 4. Mild disease correlated with a frameshift variant in exon 1 with a predicted re-initiation in exon 2; a splice variant that created a new strong donor site in intron 4; and a large genomic deletion spanning exon 6. Our findings revealed correlations between disease severity, DNA repair capacity, and XPA variant type and location. In addition, both XPA alleles contributed to the phenotypic differences in XP-A patients. Xeroderma pigmentosum, (XP), is a rare autosomal recessive inherited disease. Exposure to ultraviolet radiation greatly increases the risk of developing skin cancers and premature aging features in XP patients. In Japan, most XP-A patients have a founder variant in intron 3 of the XPA gene and experience severe neurological symptoms and death at an early age. However, in our cohort we identified different germline variants in the XPA gene associated with severe and mild clinical features in the patients. To assess XP-A patients with a wider range of disease severity, we developed a simple neurological scoring scale. Using an age of evaluation of 10 years, we categorized phenotypic differences among our 18 XP-A patients and classified them into severe, intermediate, and mild disease groups. Using this scale, we associated these 18 pathogenic variants with severe (n = 8), intermediate (n = 6), and mild (n = 4) clinical phenotypes in the XP-A patients. As a result, our scale helps predict neurological severity and mortality, making it a useful tool for general clinical practice and genotype-phenotype studies. This allowed us to correlate neurological severity with the type, location, and cellular function of XPA germline pathogenic variants.

Insights from multi-omic modeling of neurodegeneration in xeroderma pigmentosum using an induced pluripotent stem cell system

Modeling Xeroderma Pigmentosum Associated Neurological Pathologies with Patients-Derived Ipscs

Generation of Xeroderma Pigmentosum-A Patient-Derived Induced Pluripotent Stem Cell Line for Use As Future Disease Model

Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression

Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair

Revealing the UV response of melanocytes in xeroderma pigmentosum group A using patient-derived induced pluripotent stem cells

Distinctive features of single nucleotide alterations in induced pluripotent stem cells with different types of DNA repair deficiency disorders

XPC initiation codon mutation in xeroderma pigmentosum patients with and without neurological symptoms

Cell migration is impaired in XPA-deficient cells

Genomic mutation landscape of skin cancers from DNA repair-deficient xeroderma pigmentosum patients

Generation and characterization of CRISPR-Cas9-Mediated Gene Knockout in Human Skin Cells

Age-Dependent Effects of UV Exposure and Xeroderma Pigmentosum Group A on DNA Damage, Repair Mechanisms, Genomic Instability, Cancer Risk, and Neurological Disorders

Different germline variants in the XPA gene are associated with severe, intermediate, or mild neurodegeneration in xeroderma pigmentosum patients

Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients

A loss-of-function mutation in human Oxidation Resistance 1 disrupts the spatial-temporal regulation of histone arginine methylation in neurodevelopment

Molecular analysis directs the prognosis, management and treatment of patients with xeroderma pigmentosum

Human XPG Nuclease Structure, Assembly, and Activities with Insights for Neurodegeneration and Cancer from Pathogenic Mutations

Xeroderma Pigmentosum C: A Valuable Tool to Decipher the Signaling Pathways in Skin Cancers

Whole Exome Sequencing of a Patient with a Milder Phenotype of Xeroderma Pigmentosum Group C

Evidence for persistent UV-induced DNA damage and altered DNA damage response in xeroderma pigmentosa patient corneas

Deep intronic founder mutations identified in the ERCC4/ XPF gene are potential therapeutic targets for a high-frequency form of xeroderma pigmentosum